Walmart Clears Out 4K Onn Roku TVs from Just $74 in This Massive July 4th Deal
All of these models are available right now with no need to do anything special other than order your TV before the deals come to an end. Some even come with a slew of Apple services freebies, including Apple TV Plus.
The entry-level 24-inch Onn Roku smart TV is perfect for small bedrooms and kitchen counters, and at just $74, it's hard to beat. That's a $64 discount, and a real bargain if you're in the market for a small-screen model. It's only a 720p display, but that's more than enough at this size.
Hey, did you know? CNET Deals texts are free, easy and save you money.
At the opposite end of the scale, we have the 65-inch LED Roku smart TV that's now yours for just $298. That's a $50 discount and features an upgrade to 4K support for improved image quality. At this size, you really do need it, too.
Somewhere in the middle, we have the 50-inch 4K LED version of the same TV, now yours for just $178. This model represents a massive $151 discount and might just be the sweet spot for most people.
Walmart is clearing out its Roku-powered TVs as it gets ready to make the switch to new models running Vizio software, hence the sale. But these TVs still offer wireless access to all of your favorite streaming apps and services, and, at these prices, you really can't go wrong.
Be sure to check out the full range of Onn Roku TVs to see whether there's a better deal for you -- there are plenty of options across the different price and size ranges for you to choose from.
Best 4th of July TV Sales
Our shopping experts have checked through every July 4th TV deal available anywhere, and rounded up the best discounts for you to take advantage of while there's still time.
See Now
Why this deal matters
You can't beat upgrading your TV when it comes to improving your movie-watching and gaming experience. But whether you're buying for a home theater or just need to put a TV in your kid's bedroom, these deals have something for everyone. And with prices starting at just $74, they won't break the bank, either.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Truist Lifts COPT Defense Properties (CDP) PT to $30
COPT Defense Properties (NYSE:CDP) is one of the most undervalued stocks. On June 10, Truist maintained a Hold rating on CDP and raised the price target from $29 to $30. With a robust 4.31% yield, the company has consistently paid dividends for the past 34 years, indicating its commitment to shareholder returns. The target price update reflects a refined valuation approach that involves discounted cash flow analysis along with forecasted net asset value. Analysts reported that COPT Defense Properties (NYSE:CDP) is advancing three developments set to launch in 2025, with more projects on deck for 2026 and 2027. The $308 million active portfolio is 62% pre-leased, with 30% of the costs already invested. Occupancy at COPT Defense is forecasted to dip slightly to 91.9% by the end of 2025, compared to 92.3% in the first quarter. The firm also projects a low single-digit positive increase in GAAP rental spreads. A security guard patrolling a defense facility, protecting critical technologies. Analysts indicate that COPT Defense Properties (NYSE:CDP) is unlikely to engage in any mergers, acquisitions, or property disposals in 2025. However, they are factoring in a $400 million unsecured note issuance for the fourth quarter. COPT Defense, a self-managed REIT, focuses on the ownership, operation, and development of mission-critical real estate assets located near or within major US Government defense installations. While we acknowledge the potential of CDP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
UnitedHealth Stock Is One of the Worst-Performing S&P 500 Stocks in 2025. Should You Buy the Dip?
Wall Street is cheering fresh highs as the S&P 500 Index ($SPX) wraps a solid second quarter, closing June 2025 strong. The rally has been powered by cooling inflation, resilient earnings, and fading tariff concerns after April's policy shock. Just three months back, the market briefly dipped toward bear territory amid geopolitical tensions, China's AI push, tariff fears, and fiscal uncertainty, keeping investors on edge about the rebound's staying power. Despite the S&P rallying over 28% from its April lows of $4,835, the bull run has still left many big names behind. Nearly a third of the index's stocks still ended the first half of 2025 in the red. UnitedHealth (UNH), a giant in health insurance and managed care services, has plunged 39% so far in 2025. UNH stock has been hit by soaring Medicare Advantage costs, a probe into Medicare fraud, and a sudden CEO exit, making it the index's fourth-worst performer. Michael Saylor Says 'You'll Wish You'd Bought More' Bitcoin as MicroStrategy Doubles Down Is Microsoft Stock About to Go Nuclear? Is Super Micro Computer Stock a Buy, Sell, or Hold for July 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! While UNH is at five-year lows, a 1.8% five-day bounce hints at some life. With the dividend-paying stock halved and trading at a compelling valuation, is this a classic 'buy the dip' setup? Or a moment for caution despite the allure of value and yield? Founded in 1977, UnitedHealth has grown into a $295 billion healthcare heavyweight. With its deep roots in health insurance and care services, the company runs on two powerhouse engines: UnitedHealthcare and Optum. UnitedHealthcare handles the insurance side, offering plans that serve over 50 million people. It's the backbone, giving the company scale, reach, and reliable revenue. But it's Optum that brings the spark, driving growth through data, tech, and pharmacy solutions. From analytics to care delivery, Optum's strategy pushes innovation across the system. Together, these segments give the company its edge in a complex healthcare landscape. UNH stock has been in free fall in 2025, hitting a low of $248.88 in May. Over the past 52 weeks, the stock has declined 38%, trailing far behind the broader S&P's surge of 13%. However, UNH stock is rebounding, up 1% over the past month. UnitedHealth's downfall in 2025 was not just a single bad headline. It was a chain reaction that started fast and spiraled hard. It kicked off on April 17, when the company shocked the Street by slashing its full-year earnings forecast. This was because a flood of higher-acuity Medicare Advantage patients drove costs far beyond expectations, exposing just how outdated and fragile their forecasting models had become. Then May hit like a wrecking ball. CEO Andrew Witty abruptly resigned, raising eyebrows amid growing pressure. Days later, reports surfaced of a U.S. Department of Justice investigation into alleged Medicare fraud. By mid-May, the stock had crashed, hitting five-year lows. Just when it seemed the damage was done, more scandal dropped with accusations of UnitedHealth secretly paying nursing homes to avoid costly hospital transfers. Even insider buying gave only a brief lift to UNH. In a short span, UnitedHealth went from a rock-solid name to a cautionary tale unraveling in real time. After its brutal springtime plunge, UNH stock is priced at 14 times forward earnings and 0.7 times sales, trading in bargain territory. Those multiples sit well below both the sector medians and its own five-year averages, catching the eye of value hunters sniffing out a possible rebound. Despite the stock's decline, UnitedHealth has signaled some confidence where it counts: dividends. In June, the company hiked its quarterly payout by 5.2% to $2.21, marking 15 consecutive years of increases. Paid out on June 24, the hike pushed its annual yield near 2.6%. On April 17, UnitedHealth reported Q1 2025 earnings, and it wasn't the kind of update Wall Street wanted to hear. Revenue climbed 9.8% year-over-year (YOY) to $109.6 billion but still came in shy of expectations. Adjusted EPS rose 4.2% to $7.20 yet missed the estimated mark of $7.27. UnitedHealthcare, the insurance arm, posted a solid 12.2% revenue gain to $84.6 billion. Meanwhile, Optum saw more modest growth of 4.6% to $63.9 billion, with Optum Rx doing the heavy lifting. Still, rising costs loomed large. Total operating expenses surged 9.4% annually to $100.5 billion. On the brighter side, the company exited the quarter with $34.3 billion in cash and short-term investments and generated $5.5 billion in operating cash flow. Shareholders weren't left in the cold either, with over $5 billion returned through buybacks and dividends. UnitedHealth's steep selloff wasn't just about Q1 results. It was the guidance cut that really rattled sentiment. Management slashed its 2025 adjusted EPS outlook to between $26 and $26.50, down from the initially forecast range of $29.50 to $30 in December 2024 and below fiscal 2024 adjusted EPS of $27.66. Surging Medicare Advantage costs and shifts in Optum's patient mix have taken a real bite. Now, all eyes are on the fiscal Q2 report, expected to be released on July 29 before the market opens. Analysts forecast the Q2 bottom line to be around $5.08 per share, down 25% YOY. Looking to fiscal 2025, adjusted EPS is expected to decline 20% annually to $22.07, then surge by 15% to $25.39 in fiscal 2026. Last Wednesday, UBS reiterated its 'Buy' rating on UNH stock but trimmed the price target to $385 from $400. The cut followed CEO Stephen Hemsley's cautious tone at the June 2 meeting, hinting at more conservative 2025 guidance. UBS anticipates fiscal 2025 EPS closer to $20, down from the earlier $22.50 consensus. Margins were also revised, with Medicare Advantage trimmed to 1.5% and Optum Health lowered to 4.5%. Despite the recent shakeups, Wall Street hasn't completely hit the panic button yet. Last month, UnitedHealth shook things up by axing broker commissions on select Medicare Advantage plans — a move aimed at trimming the cost that forced it to yank full-year guidance. Hightower Chief Investment Strategist Stephanie Link called it a smart pivot, saying the same issue 'got them in trouble' to begin with. Link is bracing for short-term volatility but stays bullish long-term, calling UNH stock 'too cheap' for a top-tier name in the industry. There's still optimism in the air, but with a touch of caution. UNH stock has a 'Moderate Buy' consensus overall, down from a consensus 'Strong Buy' rating a month ago. Of the 24 analysts covering the stock, 15 advise a 'Strong Buy,' two suggest a 'Moderate Buy,' and seven analysts play it safe with a 'Hold.' The mean price target of $363.43 implies shares could rise as much as 18%. The Street-high target of $440, way below this year's highs, signals that UNH has an upside potential of 43% from current levels. The U.S. healthcare industry, despite constant political firestorms, is built to endure. For years, UnitedHealth has stood as its crown jewel. Defensive, dividend-paying, and shock-resistant, it has been the kind of stock long-term investors can count on. But 2025 has shattered that illusion. While the broader market climbs to record highs, UnitedHealth's dramatic plunge reminds us that even giants can stumble hard. Sure, UNH stock now trades at a discount, offering an attractive dividend yield. Insiders are buying shares, and UnitedHealth still commands significant market share and robust cash flow. But is this really a 'buy the dip' moment? It's probably a bet that management can steady the ship, and the storm eventually clears. Until then, UnitedHealth sits in a gray zone between legacy and uncertainty, where long-term promise collides with short-term pain. Investors should exercise caution before jumping in. On the date of publication, Sristi Suman Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Prologis (PLD) To Add 4000 Homes with Caltrain Site Revamp
Prologis, Inc. (NYSE:PLD) is one of the most undervalued stocks. Prologis recently indicated its intention to file redevelopment plans later this year for the Caltrain railyards located at Fourth and King Street. The REIT is proposing a seven-million-square-foot mixed-use project that could accommodate between 1,500 and 4,000 residential units. As reported by the San Francisco Business Times, if fully executed, the development would represent one of the most significant housing initiatives near a major transit corridor in San Francisco. The Business Times noted that the variability in potential housing units offers Prologis the agility to align the project with future demand. Although formal approvals are unlikely before 2027, planning commissioners are already highlighting the importance of affordability. A large logistic facility within the industrial real estate sector. Prologis Vice President Genevieve Cadwalader commented that residential development will be a focal element in the transformation of the railyards into a high-density, transit-oriented urban district. This project holds the potential to be San Francisco's second most densely developed transit-centric neighborhood, following the Transbay district. Prologis, Inc. (NYSE:PLD) is a global REIT focused on high-barrier, high-growth markets in 20 countries. Prologis leases modern logistics facilities to a diverse base of customers across two major categories – business-to-business and retail/online fulfillment. While we acknowledge the potential of PLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio
